The First Thing to Understand: There Is No Single ”Price” for a Prescription
When you think about the price of a gallon of milk or a tank of gas, there is a real market price, the amount the store paid for the product plus a markup, that is relatively transparent and relatively consistent across similar retailers.
Prescription drug pricing does not work this way. There are multiple different prices for the same prescription depending on who is paying, which insurance plan is involved, which pharmacy benefit manager administers the plan, whether a discount card is being used, and what contractual relationships exist between the pharmacy and every entity in the chain.
The prices include:
The Wholesale Acquisition Cost (WAC), the list price that a manufacturer publishes for sales to wholesalers. This is the starting point but almost nobody actually pays it.
The Average Wholesale Price (AWP), a benchmark price derived from WAC that is used in many insurance contract calculations. It is sometimes called the ”sticker price” and similarly almost nobody pays it directly.
The Maximum Allowable Cost (MAC), the maximum amount a pharmacy benefit manager will reimburse a pharmacy for a generic drug. This is a key number that varies by PBM and is one of the main drivers of price differences between pharmacies.
The negotiated contract rate, the actual amount a pharmacy receives from an insurance plan for a given drug, determined by the contract between the pharmacy and the PBM that administers the plan.
The cash price, what a patient pays if they present no insurance and no discount card. This can be the highest price at a retail pharmacy or, in some cases, surprisingly low, particularly for generic medications where pharmacies compete for cash paying customers.
The discount card price, what a patient pays when using a program like GoodRx, RxSaver, or a manufacturer coupon. This price is negotiated by the discount card company with individual pharmacies and can differ significantly between pharmacies for the same drug.
None of these prices are publicly posted in a standardized, transparent way. You are expected to navigate them without a map.
The Role of Pharmacy Benefit Managers
Pharmacy Benefit Managers, PBMs, are the middlemen of the prescription drug supply chain. They are companies hired by insurance plans, employers, and government programs to manage prescription drug benefits. The three largest PBMs, CVS Caremark, Express Scripts, and OptumRx, manage drug benefits for the majority of insured Americans.
PBMs negotiate drug prices with manufacturers, create the formularies that determine which drugs are covered at which tier, reimburse pharmacies for filled prescriptions, and set the rules that determine what you pay at the counter.
The critical and often unacknowledged fact about PBMs is that two of the three largest ones are owned by companies that also own pharmacy chains. CVS Caremark is owned by CVS Health, which operates CVS Pharmacy. OptumRx is owned by UnitedHealth Group, which has been acquiring physician practices and other healthcare entities. This vertical integration means that the company deciding how much your insurance will pay for your prescription is often also the company filling your prescription, a conflict of interest that has been the subject of significant regulatory scrutiny and ongoing litigation.
Why the Same Drug Costs Different Amounts at Different Pharmacies
When you fill a prescription at a chain pharmacy using your insurance, the pharmacy submits a claim to your PBM. The PBM reimburses the pharmacy according to the contract between them, which includes the MAC price for generic drugs and negotiated rates for brands.
Here is where price differences emerge:
Different pharmacies have different PBM contracts. An independent pharmacy’s contract with a PBM may reimburse at a different rate than a chain pharmacy’s contract. In many cases independent pharmacies are reimbursed at lower rates than large chains, a structural disadvantage that the independent pharmacy community has been fighting for years.
Different PBMs use different MAC lists. There is no standardized MAC list. Each PBM sets its own maximum allowable cost for each generic drug, and these lists vary significantly. The same generic metformin might have a MAC of $4 under one PBM and $18 under another.
Your specific insurance plan determines your copay separately from the pharmacy’s reimbursement. Your copay is set by your plan’s benefit design. The pharmacy’s reimbursement is set by the PBM contract. These two numbers are related but not identical, which creates situations where your copay exceeds the cash price of the medication, a phenomenon we will discuss in detail in a later post.
Cash prices and discount card prices vary by pharmacy. Pharmacies set their own cash prices independently. Discount card prices are negotiated individually by the discount card company with each pharmacy. This is why GoodRx shows different prices at different pharmacies for the same drug.
The DIR Fee Problem
There is one more pricing mechanism that most patients have never heard of and that has a significant impact on what independent pharmacies can charge: DIR fees.
DIR stands for Direct and Indirect Remuneration. DIR fees are amounts that PBMs charge back to pharmacies after a prescription has already been filled, sometimes months after the fact, based on quality metrics, star ratings, and other performance measures.
The practical effect of DIR fees on patients is indirect but real. When a pharmacy knows that a significant portion of its reimbursement will be clawed back months later through DIR fees, it cannot afford to price medications as competitively as it otherwise could. The fee structure that was theoretically designed to incentivize quality has become a mechanism that extracts money from pharmacies, particularly independent pharmacies, in ways that reduce their ability to serve patients.
What You Should Actually Do
Armed with this understanding, here is the practical action plan for making sure you are not overpaying for your prescriptions:
Step 1: Always check the cash price. Before presenting your insurance, ask the pharmacy what the cash price is. For generic medications, the cash price is often lower than your insurance copay, particularly if you have a high deductible plan or a plan with a deductible you have not yet met.
Step 2: Check GoodRx or a comparable discount tool. GoodRx, RxSaver, and similar programs show the discount card price at multiple nearby pharmacies. This takes about thirty seconds on your phone and can save you significant money on generic medications.
Step 3: Ask your pharmacist directly. A pharmacist who knows you can often identify the best available pricing option for your specific medication at their pharmacy. At Fairview we will always tell you the lowest legitimate price available, whether that is your insurance copay, our cash price, or a discount program.
Step 4: Ask whether a 90 day supply is cheaper per unit. For maintenance medications you take every day, a 90 day supply is often cheaper per tablet than three separate 30 day fills. This is not always the case but is worth asking.
Step 5: Compare prices across pharmacies for expensive generics. For medications where you are paying a significant amount out of pocket, a five minute phone comparison between two or three pharmacies can produce meaningful savings.
The One Sentence Honest Summary
The prescription pricing system was built by and for the benefit of large insurance companies, PBMs, and pharmaceutical manufacturers, not patients. The best protection available to you is a pharmacist who is transparent about all of your pricing options and who has no financial incentive to steer you toward the most expensive one.
This article is for general information only and is not a substitute for personalized medical advice. Before starting or changing any medication, including over the counter products and supplements, talk with your pharmacist or physician about your specific situation.
References
- FTCPharmacy Benefit Managers: The Powerful MiddlemenFederal report
- KFFUnderstanding the Prescription Drug Supply ChainPolicy analysis
